BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Quarck R, Nawrot T, Meyns B, Delcroix M. C-Reactive Protein. Journal of the American College of Cardiology 2009;53:1211-8. [DOI: 10.1016/j.jacc.2008.12.038] [Cited by in Crossref: 147] [Cited by in F6Publishing: 134] [Article Influence: 11.3] [Reference Citation Analysis]
Number Citing Articles
1 Zhang M, Zhang Y, Pang W, Zhai Z, Wang C. Circulating biomarkers in chronic thromboembolic pulmonary hypertension. Pulm Circ 2019;9:2045894019844480. [PMID: 30942132 DOI: 10.1177/2045894019844480] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
2 Huertas A, Tu L, Humbert M, Guignabert C. Chronic inflammation within the vascular wall in pulmonary arterial hypertension: more than a spectator. Cardiovasc Res. 2020;116:885-893. [PMID: 31813986 DOI: 10.1093/cvr/cvz308] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 9.5] [Reference Citation Analysis]
3 Carugno M, Consonni D, Randi G, Catelan D, Grisotto L, Bertazzi PA, Biggeri A, Baccini M. Air pollution exposure, cause-specific deaths and hospitalizations in a highly polluted Italian region. Environ Res 2016;147:415-24. [PMID: 26969808 DOI: 10.1016/j.envres.2016.03.003] [Cited by in Crossref: 76] [Cited by in F6Publishing: 60] [Article Influence: 12.7] [Reference Citation Analysis]
4 Quarck R, Wynants M, Ronisz A, Sepulveda MR, Wuytack F, Van Raemdonck D, Meyns B, Delcroix M. Characterization of proximal pulmonary arterial cells from chronic thromboembolic pulmonary hypertension patients. Respir Res 2012;13:27. [PMID: 22452949 DOI: 10.1186/1465-9921-13-27] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 2.4] [Reference Citation Analysis]
5 Hagan G, Southwood M, Treacy C, Ross RM, Soon E, Coulson J, Sheares K, Screaton N, Pepke-Zaba J, Morrell NW, Rudd JH. (18)FDG PET imaging can quantify increased cellular metabolism in pulmonary arterial hypertension: A proof-of-principle study. Pulm Circ 2011;1:448-55. [PMID: 22530099 DOI: 10.4103/2045-8932.93543] [Cited by in Crossref: 45] [Cited by in F6Publishing: 42] [Article Influence: 4.5] [Reference Citation Analysis]
6 Cracowski JL, Leuchte HH. The potential of biomarkers in pulmonary arterial hypertension. Am J Cardiol 2012;110:32S-8S. [PMID: 22921030 DOI: 10.1016/j.amjcard.2012.06.014] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.6] [Reference Citation Analysis]
7 Song XW, Zou LL, Cui L, Li SH, Qin YW, Zhao XX, Jing Q. Plasma miR-451 with echocardiography serves as a diagnostic reference for pulmonary hypertension. Acta Pharmacol Sin 2018;39:1208-16. [PMID: 29795360 DOI: 10.1038/aps.2018.39] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
8 Kanwar M, Raina A, Lohmueller L, Kraisangka J, Benza R. The Use of Risk Assessment Tools and Prognostic Scores in Managing Patients with Pulmonary Arterial Hypertension. Curr Hypertens Rep 2019;21:45. [PMID: 31025123 DOI: 10.1007/s11906-019-0950-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
9 Zhao QH, Peng FH, Wei H, He J, Chen FD, Di RM, Jiang X, Jiang R, Chen YJ, Heresi GA, Jing ZC. Serum high-density lipoprotein cholesterol levels as a prognostic indicator in patients with idiopathic pulmonary arterial hypertension. Am J Cardiol 2012;110:433-9. [PMID: 22560769 DOI: 10.1016/j.amjcard.2012.03.042] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 2.5] [Reference Citation Analysis]
10 Santos M, Reis A, Gonçalves F, Ferreira-Pinto MJ, Cabral S, Torres S, Leite-Moreira AF, Henriques-Coelho T. Adiponectin levels are elevated in patients with pulmonary arterial hypertension. Clin Cardiol 2014;37:21-5. [PMID: 24114971 DOI: 10.1002/clc.22210] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
11 Marra AM, Bossone E, Salzano A, D’assante R, Monaco F, Ferrara F, Arcopinto M, Vriz O, Suzuki T, Cittadini A. Biomarkers in Pulmonary Hypertension. Heart Failure Clinics 2018;14:393-402. [DOI: 10.1016/j.hfc.2018.03.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
12 Kones R. Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease--a perspective. Drug Des Devel Ther 2010;4:383-413. [PMID: 21267417 DOI: 10.2147/DDDT.S10812] [Cited by in Crossref: 67] [Cited by in F6Publishing: 26] [Article Influence: 5.6] [Reference Citation Analysis]
13 Jabagi H, Mielniczuk LM, Liu PP, Ruel M, Sun LY. Biomarkers in the Diagnosis, Management, and Prognostication of Perioperative Right Ventricular Failure in Cardiac Surgery-Are We There Yet? J Clin Med 2019;8:E559. [PMID: 31027170 DOI: 10.3390/jcm8040559] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
14 Muangchan C, Harding S, Khimdas S, Bonner A, Baron M, Pope J; Canadian Scleroderma Research Group. Association of C-reactive protein with high disease activity in systemic sclerosis: Results from the Canadian Scleroderma Research Group. Arthritis Care Res 2012;64:1405-14. [DOI: 10.1002/acr.21716] [Cited by in Crossref: 64] [Cited by in F6Publishing: 57] [Article Influence: 6.4] [Reference Citation Analysis]
15 Karavolias GK, Georgiadou P, Gkouziouta A, Kariofillis P, Karabela G, Tsiapras D, Sbarouni E, Chaidaroglou A, Degiannis D, Adamopoulos S, Voudris V. Short and long term anti-inflammatory effects of bosentan therapy in patients with pulmonary arterial hypertension: relation to clinical and hemodynamic responses. Expert Opinion on Therapeutic Targets 2010;14:1283-9. [DOI: 10.1517/14728222.2010.523421] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
16 Maciocia PM. Inflammatory Signaling in Pulmonary Arterial Hypertension: The Controversial Role of CRP, and the Search for New Therapies. Cardiovascular Therapeutics 2010;28:1-4. [DOI: 10.1111/j.1755-5922.2009.00128.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
17 Lavie CJ, Milani RV, Verma A, O’keefe JH. C-Reactive Protein and Cardiovascular Diseases—Is it Ready for Primetime? The American Journal of the Medical Sciences 2009;338:486-92. [DOI: 10.1097/maj.0b013e3181c61b66] [Cited by in Crossref: 49] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
18 Price LC, Wort SJ, Perros F, Dorfmüller P, Huertas A, Montani D, Cohen-Kaminsky S, Humbert M. Inflammation in pulmonary arterial hypertension. Chest 2012;141:210-21. [PMID: 22215829 DOI: 10.1378/chest.11-0793] [Cited by in Crossref: 242] [Cited by in F6Publishing: 224] [Article Influence: 24.2] [Reference Citation Analysis]
19 Papageorgiou N, Tousoulis D, Androulakis E, Antoniades C, Tentolouris C, Stefanadis C. Inflammation and right ventricle: the hunting of the missing link. Int J Cardiol 2013;168:3152-4. [PMID: 23910446 DOI: 10.1016/j.ijcard.2013.07.082] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
20 Alias S, Redwan B, Panzenboeck A, Winter MP, Schubert U, Voswinckel R, Frey MK, Jakowitsch J, Alimohammadi A, Hobohm L, Mangold A, Bergmeister H, Sibilia M, Wagner EF, Mayer E, Klepetko W, Hoelzenbein TJ, Preissner KT, Lang IM. Defective angiogenesis delays thrombus resolution: a potential pathogenetic mechanism underlying chronic thromboembolic pulmonary hypertension. Arterioscler Thromb Vasc Biol 2014;34:810-9. [PMID: 24526692 DOI: 10.1161/ATVBAHA.113.302991] [Cited by in Crossref: 65] [Cited by in F6Publishing: 24] [Article Influence: 8.1] [Reference Citation Analysis]
21 Carretón E, Morchón R, Montoya-Alonso JA. Cardiopulmonary and inflammatory biomarkers in heartworm disease. Parasit Vectors 2017;10:534. [PMID: 29143665 DOI: 10.1186/s13071-017-2448-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
22 Swinnen K, Bijnens E, Casas L, Nawrot TS, Delcroix M, Quarck R, Belge C. Residential air pollution increases the risk for persistent pulmonary hypertension after pulmonary endarterectomy. Eur Respir J 2021;57:2002680. [PMID: 33479106 DOI: 10.1183/13993003.02680-2020] [Reference Citation Analysis]
23 Heresi GA. Clinical perspective: biomarkers in pulmonary arterial hypertension. Int J Clin Pract Suppl 2011;:5-7. [PMID: 21176009 DOI: 10.1111/j.1742-1241.2010.02598.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
24 Kopeć G, Waligóra M, Tyrka A, Jonas K, Pencina MJ, Zdrojewski T, Moertl D, Stokwiszewski J, Zagożdżon P, Podolec P. Low-density lipoprotein cholesterol and survival in pulmonary arterial hypertension. Sci Rep 2017;7:41650. [PMID: 28198422 DOI: 10.1038/srep41650] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
25 Malhotra R, Paskin-Flerlage S, Zamanian RT, Zimmerman P, Schmidt JW, Deng DY, Southwood M, Spencer R, Lai CS, Parker W, Channick RN, Morrell NW, Elliott CG, Yu PB. Circulating angiogenic modulatory factors predict survival and functional class in pulmonary arterial hypertension. Pulm Circ 2013;3:369-80. [PMID: 24015338 DOI: 10.4103/2045-8932.110445] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 3.8] [Reference Citation Analysis]
26 Liu H, Yang E, Lu X, Zuo C, He Y, Jia D, Zhu Q, Yu Y, Lv A. Serum levels of tumor necrosis factor-related apoptosis-inducing ligand correlate with the severity of pulmonary hypertension. Pulm Pharmacol Ther 2015;33:39-46. [PMID: 26086178 DOI: 10.1016/j.pupt.2015.06.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
27 Holzhauser L, Hovnanians N, Eshtehardi P, Mojadidi MK, Deng Y, Goodman-meza D, Msaouel P, Ko Y, Zolty R. Statin therapy improves survival in patients with severe pulmonary hypertension: a propensity score matching study. Heart Vessels 2017;32:969-76. [DOI: 10.1007/s00380-017-0957-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
28 Kariotis S, Jammeh E, Swietlik EM, Pickworth JA, Rhodes CJ, Otero P, Wharton J, Iremonger J, Dunning MJ, Pandya D, Mascarenhas TS, Errington N, Thompson AAR, Romanoski CE, Rischard F, Garcia JGN, Yuan JX, An TS, Desai AA, Coghlan G, Lordan J, Corris PA, Howard LS, Condliffe R, Kiely DG, Church C, Pepke-Zaba J, Toshner M, Wort S, Gräf S, Morrell NW, Wilkins MR, Lawrie A, Wang D; UK National PAH Cohort Study Consortium. Biological heterogeneity in idiopathic pulmonary arterial hypertension identified through unsupervised transcriptomic profiling of whole blood. Nat Commun 2021;12:7104. [PMID: 34876579 DOI: 10.1038/s41467-021-27326-0] [Reference Citation Analysis]
29 Lepsy N, Dering M, Fuge J, Meltendorf T, Hoeper MM, Heitland I, Kamp JC, Park D, Richter MJ, Gall H, Ghofrani HA, Ellermeier D, Kulla H, Olsson KM, Kahl KG. Childhood Maltreatment, Mental Well-Being, and Healthy Lifestyle in Patients With Chronic Thromboembolic Pulmonary Hypertension. Front Psychiatry 2022;13:821468. [DOI: 10.3389/fpsyt.2022.821468] [Reference Citation Analysis]
30 McNeill JN, Lau ES, Zern EK, Nayor M, Malhotra R, Liu EE, Bhat RR, Brooks LC, Farrell R, Sbarbaro JA, Schoenike MW, Medoff BD, Lewis GD, Ho JE. Association of obesity-related inflammatory pathways with lung function and exercise capacity. Respir Med 2021;183:106434. [PMID: 33964816 DOI: 10.1016/j.rmed.2021.106434] [Reference Citation Analysis]
31 Bryce YC, Perez-Johnston R, Bryce EB, Homayoon B, Santos-Martin EG. Pathophysiology of right ventricular failure in acute pulmonary embolism and chronic thromboembolic pulmonary hypertension: a pictorial essay for the interventional radiologist. Insights Imaging 2019;10:18. [PMID: 30758687 DOI: 10.1186/s13244-019-0695-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
32 Hewes JL, Lee JY, Fagan KA, Bauer NN. The changing face of pulmonary hypertension diagnosis: a historical perspective on the influence of diagnostics and biomarkers. Pulm Circ 2020;10:2045894019892801. [PMID: 32110383 DOI: 10.1177/2045894019892801] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
33 Cuttica MJ, Langenickel T, Noguchi A, Machado RF, Gladwin MT, Boehm M. Perivascular T-cell infiltration leads to sustained pulmonary artery remodeling after endothelial cell damage. Am J Respir Cell Mol Biol 2011;45:62-71. [PMID: 20813993 DOI: 10.1165/rcmb.2009-0365OC] [Cited by in Crossref: 26] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
34 Pezzuto B, Badagliacca R, Poscia R, Ghio S, D’alto M, Vitulo P, Mulè M, Albera C, Volterrani M, Fedele F, Vizza CD. Circulating biomarkers in pulmonary arterial hypertension: Update and future direction. The Journal of Heart and Lung Transplantation 2015;34:282-305. [DOI: 10.1016/j.healun.2014.12.005] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 5.0] [Reference Citation Analysis]
35 Gabriel Botella F, Labiós Gómez M, Corella Piquer D. [Chronic thromboembolic pulmonary hypertension]. Med Clin (Barc) 2012;139:215-20. [PMID: 22565100 DOI: 10.1016/j.medcli.2012.02.016] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
36 Nickel NP, de Jesus Perez VA, Zamanian RT, Fessel JP, Cogan JD, Hamid R, West JD, de Caestecker MP, Yang H, Austin ED. Low-grade albuminuria in pulmonary arterial hypertension. Pulm Circ 2019;9:2045894018824564. [PMID: 30632900 DOI: 10.1177/2045894018824564] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
37 Perros F, Montani D, Dorfmüller P, Huertas A, Chaumais MC, Cohen-Kaminsky S, Humbert M. [Novel immunopathological approaches to pulmonary arterial hypertension]. Presse Med 2011;40 Suppl 1:1S3-13. [PMID: 21536178 DOI: 10.1016/S0755-4982(11)70002-1] [Cited by in Crossref: 4] [Article Influence: 0.4] [Reference Citation Analysis]
38 Leuchte HH, Ten Freyhaus H, Gall H, Halank M, Hoeper MM, Kaemmerer H, Kähler C, Riemekasten G, Ulrich S, Schwaiblmair M, Ewert R. Risk stratification strategy and assessment of disease progression in patients with pulmonary arterial hypertension: Updated Recommendations from the Cologne Consensus Conference 2018. Int J Cardiol 2018;272S:20-9. [PMID: 30266353 DOI: 10.1016/j.ijcard.2018.08.084] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
39 Al-Naamani N, Palevsky HI, Lederer DJ, Horn EM, Mathai SC, Roberts KE, Tracy RP, Hassoun PM, Girgis RE, Shimbo D, Post WS, Kawut SM; ASA-STAT Study Group. Prognostic Significance of Biomarkers in Pulmonary Arterial Hypertension. Ann Am Thorac Soc 2016;13:25-30. [PMID: 26501464 DOI: 10.1513/AnnalsATS.201508-543OC] [Cited by in Crossref: 32] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
40 Xu X, Lv Z, Liu Q, Zhao Q, Wu Y, Sun K, Jiang X, Wang L, Peng F, Jing Z. Direct bilirubin: A new risk factor of adverse outcome in idiopathic pulmonary arterial hypertension. International Journal of Cardiology 2017;228:895-9. [DOI: 10.1016/j.ijcard.2016.11.036] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
41 Quarck R, Wynants M, Verbeken E, Meyns B, Delcroix M. Contribution of inflammation and impaired angiogenesis to the pathobiology of chronic thromboembolic pulmonary hypertension. Eur Respir J 2015;46:431-43. [DOI: 10.1183/09031936.00009914] [Cited by in Crossref: 66] [Cited by in F6Publishing: 57] [Article Influence: 9.4] [Reference Citation Analysis]
42 Gu S, Su P, Yan J, Zhang X, An X, Gao J, Xin R, Liu Y. Comparison of gene expression profiles and related pathways in chronic thromboembolic pulmonary hypertension. Int J Mol Med 2014;33:277-300. [PMID: 24337368 DOI: 10.3892/ijmm.2013.1582] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
43 Hennigs JK, Baumann HJ, Lüneburg N, Quast G, Harbaum L, Heyckendorf J, Sydow K, Schulte-Hubbert B, Halank M, Klose H. Fibrinogen plasma concentration is an independent marker of haemodynamic impairment in chronic thromboembolic pulmonary hypertension. Sci Rep 2014;4:4808. [PMID: 24770447 DOI: 10.1038/srep04808] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
44 Venco L, Bertazzolo W, Giordano G, Paltrinieri S. Evaluation of C-reactive protein as a clinical biomarker in naturally heartworm-infected dogs: a field study. Vet Parasitol 2014;206:48-54. [PMID: 25218887 DOI: 10.1016/j.vetpar.2014.08.018] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
45 Fernandes T, Planquette B, Sanchez O, Morris T. From Acute to Chronic Thromboembolic Disease. Ann Am Thorac Soc 2016;13 Suppl 3:S207-14. [PMID: 27571002 DOI: 10.1513/AnnalsATS.201509-619AS] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 2.8] [Reference Citation Analysis]
46 Brittain EL, Nwabuo C, Xu M, Gupta DK, Hemnes AR, Moreira HT, De Vasconcellos HD, Terry JG, Carr JJ, Lima JA. Echocardiographic Pulmonary Artery Systolic Pressure in the Coronary Artery Risk Development in Young Adults (CARDIA) Study: Associations With Race and Metabolic Dysregulation. J Am Heart Assoc 2017;6:e005111. [PMID: 28360228 DOI: 10.1161/JAHA.116.005111] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.6] [Reference Citation Analysis]
47 Oz-Tuncer G, Olgunturk R, Pektas A, Cilsal E, Kula S, Oguz DA, Tunaoglu SF, Pasaoglu OT, Pasaoglu H. The role of inflammatory biomarkers in CHD-associated pulmonary hypertension in children. Cardiol Young 2017;27:255-60. [PMID: 28366184 DOI: 10.1017/S1047951116000408] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
48 Jaff MR, McMurtry MS, Archer SL, Cushman M, Goldenberg N, Goldhaber SZ, Jenkins JS, Kline JA, Michaels AD, Thistlethwaite P, Vedantham S, White RJ, Zierler BK; American Heart Association Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation; American Heart Association Council on Peripheral Vascular Disease; American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation. 2011;123:1788-1830. [PMID: 21422387 DOI: 10.1161/cir.0b013e318214914f] [Cited by in Crossref: 1307] [Cited by in F6Publishing: 352] [Article Influence: 118.8] [Reference Citation Analysis]
49 Sydykov A, Mamazhakypov A, Petrovic A, Kosanovic D, Sarybaev AS, Weissmann N, Ghofrani HA, Schermuly RT. Inflammatory Mediators Drive Adverse Right Ventricular Remodeling and Dysfunction and Serve as Potential Biomarkers. Front Physiol 2018;9:609. [PMID: 29875701 DOI: 10.3389/fphys.2018.00609] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
50 Coz Yataco A, Aguinaga Meza M, Buch KP, Disselkamp MA. Hospital and intensive care unit management of decompensated pulmonary hypertension and right ventricular failure. Heart Fail Rev 2016;21:323-46. [PMID: 26486799 DOI: 10.1007/s10741-015-9514-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
51 Banaszkiewicz M, Gąsecka A, Darocha S, Florczyk M, Pietrasik A, Kędzierski P, Piłka M, Torbicki A, Kurzyna M. Circulating Blood-Based Biomarkers in Pulmonary Hypertension. J Clin Med 2022;11:383. [PMID: 35054082 DOI: 10.3390/jcm11020383] [Reference Citation Analysis]
52 McLaughlin VV, Gaine SP, Howard LS, Leuchte HH, Mathier MA, Mehta S, Palazzini M, Park MH, Tapson VF, Sitbon O. Treatment goals of pulmonary hypertension. J Am Coll Cardiol. 2013;62:D73-D81. [PMID: 24355644 DOI: 10.1016/j.jacc.2013.10.034] [Cited by in Crossref: 209] [Cited by in F6Publishing: 168] [Article Influence: 26.1] [Reference Citation Analysis]
53 Alba GA, Atri D, Darbha S, Singh I, Tapson VF, Lewis MI, Chun HJ, Yu YR, Maron BA, Rajagopal S. Chronic Thromboembolic Pulmonary Hypertension: the Bench. Curr Cardiol Rep 2021;23:141. [PMID: 34410515 DOI: 10.1007/s11886-021-01572-6] [Reference Citation Analysis]
54 Desmarais J, Elliott CG. Familial Chronic Thromboembolic Pulmonary Hypertension. Chest 2016;149:e99-e101. [DOI: 10.1016/j.chest.2015.09.017] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
55 Abul Y, Ozsu S, Korkmaz A, Bulbul Y, Orem A, Ozlu T. Red cell distribution width: A new predictor for chronic thromboembolic pulmonary hypertension after pulmonary embolism. Chron Respir Dis 2014;11:73-81. [DOI: 10.1177/1479972314525057] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
56 Renzi M, Scortichini M, Forastiere F, De' Donato F, Michelozzi P, Davoli M, Gariazzo C, Viegi G, Stafoggia M, Ancona C, Bucci S, De' Donato F, Michelozzi P, Renzi M, Scortichini M, Stafoggia M, Bonafede M, Gariazzo C, Marinaccio A, Argentini S, Sozzi R, Bonomo S, Fasola S, Forastiere F, La Grutta S, Viegi G, Cernigliaro A, Scondotto S, Baldacci S, Maio S, Licitra G, Moro A, Angelini P, Bonvicini L, Broccoli S, Ottone M, Rossi PG, Colacci A, Parmagnani F, Ranzi A, Galassi C, Migliore E, Bisceglia L, Chieti A, Brusasca G, Calori G, Finardi S, Nanni A, Pepe N, Radice P, Silibello C, Tinarelli G, Uboldi F, Carlino G; BEEP collaborative Group. A nationwide study of air pollution from particulate matter and daily hospitalizations for respiratory diseases in Italy. Sci Total Environ 2021;:151034. [PMID: 34666080 DOI: 10.1016/j.scitotenv.2021.151034] [Reference Citation Analysis]
57 Ghataorhe P, Rhodes CJ, Harbaum L, Attard M, Wharton J, Wilkins MR. Pulmonary arterial hypertension - progress in understanding the disease and prioritizing strategies for drug development. J Intern Med 2017;282:129-41. [DOI: 10.1111/joim.12623] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
58 Mathew R. Inflammation and Pulmonary Hypertension. Cardiology in Review 2010;18:67-72. [DOI: 10.1097/crd.0b013e3181cd612f] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
59 Quarck R, Delcroix M. Is inflammation a potential therapeutic target in chronic thromboembolic pulmonary hypertension? Eur Respir J 2014;44:842-5. [DOI: 10.1183/09031936.00120014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
60 Säleby J, Bouzina H, Lundgren J, Rådegran G. Angiogenic and inflammatory biomarkers in the differentiation of pulmonary hypertension. Scand Cardiovasc J 2017;51:261-70. [PMID: 28776404 DOI: 10.1080/14017431.2017.1359419] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
61 Kishimoto Y, Kato T, Ito M, Azuma Y, Fukasawa Y, Ohno K, Kojima S. Hydrogen ameliorates pulmonary hypertension in rats by anti-inflammatory and antioxidant effects. J Thorac Cardiovasc Surg 2015;150:645-54.e3. [PMID: 26095621 DOI: 10.1016/j.jtcvs.2015.05.052] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
62 Ranka S, Mohananey D, Agarwal N, Verma BR, Villablanca P, Mewhort HE, Ramakrishna H. Chronic Thromboembolic Pulmonary Hypertension-Management Strategies and Outcomes. J Cardiothorac Vasc Anesth 2020;34:2513-23. [PMID: 31883688 DOI: 10.1053/j.jvca.2019.11.019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
63 Amabile N, Heiss C, Chang V, Angeli FS, Damon L, Rame EJ, Mcglothlin D, Grossman W, De Marco T, Yeghiazarians Y. Increased CD62e+ Endothelial Microparticle Levels Predict Poor Outcome in Pulmonary Hypertension Patients. The Journal of Heart and Lung Transplantation 2009;28:1081-6. [DOI: 10.1016/j.healun.2009.06.005] [Cited by in Crossref: 67] [Cited by in F6Publishing: 63] [Article Influence: 5.2] [Reference Citation Analysis]
64 Minkin R, Sandhu G, Grosu H, Tartell L, Ma S, Lin YY, Eden E, Turino GM. Desmosine and Isodesmosine as a Novel Biomarker for Pulmonary Arterial Hypertension: A Pilot Study. Am J Ther 2017;24:e399-404. [PMID: 26237301 DOI: 10.1097/MJT.0000000000000260] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
65 Klinke A, Schubert T, Müller M, Legchenko E, Zelt JGE, Shimauchi T, Napp LC, Rothman AMK, Bonnet S, Stewart DJ, Hansmann G, Rudolph V. Emerging therapies for right ventricular dysfunction and failure. Cardiovasc Diagn Ther 2020;10:1735-67. [PMID: 33224787 DOI: 10.21037/cdt-20-592] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
66 Cai Z, Tian S, Klein T, Tu L, Geenen LW, Koudstaal T, van den Bosch AE, de Rijke YB, Reiss IKM, Boersma E, van der Ley C, Van Faassen M, Kema I, Duncker DJ, Boomars KA, Tran-Lundmark K, Guignabert C, Merkus D. Kynurenine metabolites predict survival in pulmonary arterial hypertension: A role for IL-6/IL-6Rα. Sci Rep 2022;12:12326. [PMID: 35853948 DOI: 10.1038/s41598-022-15039-3] [Reference Citation Analysis]
67 Yang J, Yu XX, Abulaiti A, Fei JC. Correlation between nuclear factor κB activity and pulmonary artery pressure in a rat high pulmonary blood flow model. Exp Ther Med 2015;9:543-6. [PMID: 25574231 DOI: 10.3892/etm.2014.2121] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
68 Arthur Ataam J, Amsallem M, Guihaire J, Haddad F, Lamrani L, Stephan F, Jaïs X, Humbert M, Mercier O, Fadel E. Preoperative C-reactive protein predicts early postoperative outcomes after pulmonary endarterectomy in patients with chronic thromboembolic pulmonary hypertension. J Thorac Cardiovasc Surg 2021;161:1532-1542.e5. [PMID: 32007254 DOI: 10.1016/j.jtcvs.2019.11.133] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
69 Naito A, Tanabe N, Jujo T, Shigeta A, Sugiura T, Sakao S, Ishida K, Tatsumi K. Pentraxin3 in chronic thromboembolic pulmonary hypertension: a new biomarker for screening from remitted pulmonary thromboembolism. PLoS One 2014;9:e113086. [PMID: 25412085 DOI: 10.1371/journal.pone.0113086] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
70 Yan Y, Wang X, Li S, Yang S, Lv Z, Wang L, He Y, Jiang X, Wang Y, Jing Z. Elevated levels of plasma transforming growth factor-β1 in idiopathic and heritable pulmonary arterial hypertension. International Journal of Cardiology 2016;222:368-74. [DOI: 10.1016/j.ijcard.2016.07.192] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
71 Androulakis E, Lioudaki E, Christophides T, Ahmad M, Fayed H, Laskar N, Schreiber B. Chronic thromboembolic pulmonary arterial hypertension: a review of the literature and novel therapeutic approaches. Expert Rev Respir Med 2015;9:351-9. [PMID: 25974147 DOI: 10.1586/17476348.2015.1046843] [Reference Citation Analysis]
72 Tura-Ceide O, Smolders VFED, Aventin N, Morén C, Guitart-Mampel M, Blanco I, Piccari L, Osorio J, Rodríguez C, Rigol M, Solanes N, Malandrino A, Kurakula K, Goumans MJ, Quax PHA, Peinado VI, Castellà M, Barberà JA. Derivation and characterisation of endothelial cells from patients with chronic thromboembolic pulmonary hypertension. Sci Rep 2021;11:18797. [PMID: 34552142 DOI: 10.1038/s41598-021-98320-1] [Reference Citation Analysis]
73 Magoń W, Stępniewski J, Waligóra M, Jonas K, Przybylski R, Podolec P, Kopeć G. Changes in Inflammatory Markers in Patients with Chronic Thromboembolic Pulmonary Hypertension Treated with Balloon Pulmonary Angioplasty. Cells 2022;11:1491. [DOI: 10.3390/cells11091491] [Reference Citation Analysis]
74 Vengethasamy L, Hautefort A, Tielemans B, Belge C, Perros F, Verleden S, Fadel E, Van Raemdonck D, Delcroix M, Quarck R. BMPRII influences the response of pulmonary microvascular endothelial cells to inflammatory mediators. Pflugers Arch 2016;468:1969-83. [PMID: 27816994 DOI: 10.1007/s00424-016-1899-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
75 Mercier O, Arthur Ataam J, Langer NB, Dorfmüller P, Lamrani L, Lecerf F, Decante B, Dartevelle P, Eddahibi S, Fadel E. Abnormal pulmonary endothelial cells may underlie the enigmatic pathogenesis of chronic thromboembolic pulmonary hypertension. J Heart Lung Transplant 2017;36:305-14. [PMID: 27793518 DOI: 10.1016/j.healun.2016.08.012] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
76 Harbaum L, Baaske KM, Simon M, Oqueka T, Sinning C, Glatzel A, Lüneburg N, Sydow K, Bokemeyer C, Klose H. Exploratory analysis of the neutrophil to lymphocyte ratio in patients with pulmonary arterial hypertension. BMC Pulm Med 2017;17:72. [PMID: 28446163 DOI: 10.1186/s12890-017-0407-5] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
77 Barrier M, Meloche J, Jacob MH, Courboulin A, Provencher S, Bonnet S. Today's and tomorrow's imaging and circulating biomarkers for pulmonary arterial hypertension. Cell Mol Life Sci 2012;69:2805-31. [PMID: 22446747 DOI: 10.1007/s00018-012-0950-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
78 Yanagisawa A, Naito A, Jujo-Sanada T, Tanabe N, Ishida K, Matsumiya G, Suda R, Kasai H, Sekine A, Sugiura T, Shigeta A, Sakao S, Tatsumi K, Suzuki T. Vascular involvement in chronic thromboembolic pulmonary hypertension is associated with spirometry obstructive impairment. BMC Pulm Med 2021;21:407. [PMID: 34886828 DOI: 10.1186/s12890-021-01779-x] [Reference Citation Analysis]
79 Huertas A, Perros F, Tu L, Cohen-kaminsky S, Montani D, Dorfmüller P, Guignabert C, Humbert M. Immune Dysregulation and Endothelial Dysfunction in Pulmonary Arterial Hypertension: A Complex Interplay. Circulation 2014;129:1332-40. [DOI: 10.1161/circulationaha.113.004555] [Cited by in Crossref: 98] [Cited by in F6Publishing: 40] [Article Influence: 12.3] [Reference Citation Analysis]
80 Sharma M, Levine DJ. Revisiting a Distinct Entity in Pulmonary Vascular Disease: Chronic Thromboembolic Pulmonary Hypertension (CTEPH). Medicina (Kaunas) 2021;57:355. [PMID: 33916978 DOI: 10.3390/medicina57040355] [Reference Citation Analysis]
81 Toshner M, Pepke-Zaba J. Chronic thromboembolic pulmonary hypertension: time for research in pathophysiology to catch up with developments in treatment. F1000Prime Rep 2014;6:38. [PMID: 24991415 DOI: 10.12703/P6-38] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
82 Arthur Ataam J, Mercier O, Lamrani L, Amsallem M, Arthur Ataam J, Arthur Ataam S, Guihaire J, Lecerf F, Capuano V, Ghigna MR, Haddad F, Fadel E, Eddahibi S. ICAM-1 promotes the abnormal endothelial cell phenotype in chronic thromboembolic pulmonary hypertension. J Heart Lung Transplant 2019;38:982-96. [PMID: 31324443 DOI: 10.1016/j.healun.2019.06.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
83 Pendergrass SA, Hayes E, Farina G, Lemaire R, Farber HW, Whitfield ML, Lafyatis R. Limited systemic sclerosis patients with pulmonary arterial hypertension show biomarkers of inflammation and vascular injury. PLoS One 2010;5:e12106. [PMID: 20808962 DOI: 10.1371/journal.pone.0012106] [Cited by in Crossref: 92] [Cited by in F6Publishing: 84] [Article Influence: 7.7] [Reference Citation Analysis]
84 Murthy S, Benza R. The Evolution of Risk Assessment in Pulmonary Arterial Hypertension. Methodist Debakey Cardiovasc J 2021;17:134-44. [PMID: 34326933 DOI: 10.14797/LRPR7655] [Reference Citation Analysis]
85 Swiston JR, Johnson SR, Granton JT. Factors that prognosticate mortality in idiopathic pulmonary arterial hypertension: A systematic review of the literature. Respiratory Medicine 2010;104:1588-607. [DOI: 10.1016/j.rmed.2010.08.003] [Cited by in Crossref: 58] [Cited by in F6Publishing: 56] [Article Influence: 4.8] [Reference Citation Analysis]
86 Kelley EE, Baust J, Bonacci G, Golin-Bisello F, Devlin JE, St Croix CM, Watkins SC, Gor S, Cantu-Medellin N, Weidert ER, Frisbee JC, Gladwin MT, Champion HC, Freeman BA, Khoo NK. Fatty acid nitroalkenes ameliorate glucose intolerance and pulmonary hypertension in high-fat diet-induced obesity. Cardiovasc Res 2014;101:352-63. [PMID: 24385344 DOI: 10.1093/cvr/cvt341] [Cited by in Crossref: 55] [Cited by in F6Publishing: 56] [Article Influence: 6.9] [Reference Citation Analysis]
87 Nickel NP, O'Leary JM, Brittain EL, Fessel JP, Zamanian RT, West JD, Austin ED. Kidney dysfunction in patients with pulmonary arterial hypertension. Pulm Circ 2017;7:38-54. [PMID: 28680564 DOI: 10.1086/690018] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 5.2] [Reference Citation Analysis]
88 Lang I. Chronic thromboembolic pulmonary hypertension: a distinct disease entity. Eur Respir Rev 2015;24:246-52. [DOI: 10.1183/16000617.00001115] [Cited by in Crossref: 58] [Cited by in F6Publishing: 50] [Article Influence: 8.3] [Reference Citation Analysis]
89 Sweatt AJ, Reddy R, Rahaghi FN, Al-Naamani N; American Thoracic Society Pulmonary Circulation Assembly Early Career Working Group. What's new in pulmonary hypertension clinical research: lessons from the best abstracts at the 2020 American Thoracic Society International Conference. Pulm Circ 2021;11:20458940211040713. [PMID: 34471517 DOI: 10.1177/20458940211040713] [Reference Citation Analysis]
90 Pullamsetti S, Savai R, Janssen W, Dahal B, Seeger W, Grimminger F, Ghofrani H, Weissmann N, Schermuly R. Inflammation, immunological reaction and role of infection in pulmonary hypertension. Clinical Microbiology and Infection 2011;17:7-14. [DOI: 10.1111/j.1469-0691.2010.03285.x] [Cited by in Crossref: 54] [Cited by in F6Publishing: 51] [Article Influence: 4.9] [Reference Citation Analysis]
91 Huang Z, Liu Z, Luo Q, Zhao Z, Zhao Q, Zheng Y, Xi Q, Tang Y. Glycoprotein 130 Inhibitor Ameliorates Monocrotaline-Induced Pulmonary Hypertension in Rats. Canadian Journal of Cardiology 2016;32:1356.e1-1356.e10. [DOI: 10.1016/j.cjca.2016.02.058] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
92 Liang S, Desai AA, Black SM, Tang H. Cytokines, Chemokines, and Inflammation in Pulmonary Arterial Hypertension. Adv Exp Med Biol 2021;1303:275-303. [PMID: 33788198 DOI: 10.1007/978-3-030-63046-1_15] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
93 Minai OA. Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Biomarkers in pulmonary arterial hypertension. Ann Thorac Med 2014;9:S92-7. [PMID: 25077003 DOI: 10.4103/1817-1737.134047] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
94 Konstantinides SV, Torbicki A, Agnelli G, Danchin N, Fitzmaurice D, Galiè N, Gibbs JS, Huisman MV, Humbert M, Kucher N. 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014;35:3033-3069, 3069a-3069k. [PMID: 25173341 DOI: 10.1093/eurheartj/ehu283] [Cited by in Crossref: 1523] [Cited by in F6Publishing: 1262] [Article Influence: 190.4] [Reference Citation Analysis]
95 Chen G, Yang T, Gu Q, Ni X, Zhao Z, Ye J, Meng X, Liu Z, He J, Xiong C. Elevated plasma YKL-40 as a prognostic indicator in patients with idiopathic pulmonary arterial hypertension: YKL-40 predicts outcomes in PAH. Respirology 2014;19:608-15. [DOI: 10.1111/resp.12283] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
96 Skoro-Sajer N, Gerges C, Gerges M, Panzenböck A, Jakowitsch J, Kurz A, Taghavi S, Sadushi-Kolici R, Campean I, Klepetko W, Celermajer DS, Lang IM. Usefulness of thrombosis and inflammation biomarkers in chronic thromboembolic pulmonary hypertension-sampling plasma and surgical specimens. J Heart Lung Transplant 2018;37:1067-74. [PMID: 29802084 DOI: 10.1016/j.healun.2018.04.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
97 Price LC, Caramori G, Perros F, Meng C, Gambaryan N, Dorfmuller P, Montani D, Casolari P, Zhu J, Dimopoulos K, Shao D, Girerd B, Mumby S, Proudfoot A, Griffiths M, Papi A, Humbert M, Adcock IM, Wort SJ. Nuclear factor κ-B is activated in the pulmonary vessels of patients with end-stage idiopathic pulmonary arterial hypertension. PLoS One 2013;8:e75415. [PMID: 24124488 DOI: 10.1371/journal.pone.0075415] [Cited by in Crossref: 51] [Cited by in F6Publishing: 51] [Article Influence: 5.7] [Reference Citation Analysis]
98 Renzi M, Marchetti S, De' Donato F, Pappagallo M, Scortichini M, Davoli M, Frova L, Michelozzi P, Stafoggia M. Acute Effects of Particulate Matter on All-Cause Mortality in Urban, Rural, and Suburban Areas, Italy. Int J Environ Res Public Health 2021;18:12895. [PMID: 34948503 DOI: 10.3390/ijerph182412895] [Reference Citation Analysis]
99 DuBrock HM, AbouEzzeddine OF, Redfield MM. High-sensitivity C-reactive protein in heart failure with preserved ejection fraction. PLoS One 2018;13:e0201836. [PMID: 30114262 DOI: 10.1371/journal.pone.0201836] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 8.3] [Reference Citation Analysis]
100 de Perrot M, Gopalan D, Jenkins D, Lang IM, Fadel E, Delcroix M, Benza R, Heresi GA, Kanwar M, Granton JT, McInnis M, Klok FA, Kerr KM, Pepke-Zaba J, Toshner M, Bykova A, Armini AM, Robbins IM, Madani M, McGiffin D, Wiedenroth CB, Mafeld S, Opitz I, Mercier O, Uber PA, Frantz RP, Auger WR. Evaluation and management of patients with chronic thromboembolic pulmonary hypertension - consensus statement from the ISHLT. J Heart Lung Transplant 2021;40:1301-26. [PMID: 34420851 DOI: 10.1016/j.healun.2021.07.020] [Reference Citation Analysis]
101 Haoming S, Lemin W, Zhu G, Aibin L, Yuan X, Wei L, Jinfa J, Wenjun X, Yuqin S. T cell-mediated immune deficiency or compromise in patients with CTEPH. Am J Respir Crit Care Med 2011;183:417-8. [PMID: 21288869 DOI: 10.1164/ajrccm.183.3.417] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
102 Renard S, Paulin R, Breuils-Bonnet S, Simard S, Pibarot P, Bonnet S, Provencher S. Pim-1: A new biomarker in pulmonary arterial hypertension. Pulm Circ 2013;3:74-81. [PMID: 23662177 DOI: 10.4103/2045-8932.109917] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
103 Hassoun PM, Nikkho S, Rosenzweig EB, Moreschi G, Lawrence J, Teeter J, Meier C, Ghofrani AH, Minai O, Rinaldi P, Michelakis E, Oudiz RJ. Updating clinical endpoint definitions. Pulm Circ 2013;3:206-16. [PMID: 23662199 DOI: 10.4103/2045-8932.109920] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
104 Papa S, Miotti C, Manzi G, Scoccia G, Luongo F, Toto F, Malerba C, Cedrone N, Canuti ES, Caputo A, Manguso G, Valentini S, Sciomer S, Ciciarello F, Benedetti G, Fedele F, Vizza CD, Badagliacca R. Peripheral Arterial Stiffness in Acute Pulmonary Embolism and Pulmonary Hypertension at Short-Term Follow-Up. J Clin Med 2021;10:3008. [PMID: 34300176 DOI: 10.3390/jcm10143008] [Reference Citation Analysis]
105 Klok F, Surie S, Kempf T, Eikenboom J, van Straalen J, van Kralingen K, van Dijk A, Vliegen H, Bresser P, Wollert K, Huisman M. A simple non-invasive diagnostic algorithm for ruling out chronic thromboembolic pulmonary hypertension in patients after acute pulmonary embolism. Thrombosis Research 2011;128:21-6. [DOI: 10.1016/j.thromres.2011.03.004] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 3.9] [Reference Citation Analysis]
106 Cerik IB, Dindas F, Koyun E, Dereli S, Sahin A, Turgut OO, Gul I. New prognostic markers in pulmonary arterial hypertension: CRP to albumin ratio and uric acid. Clin Biochem 2021:S0009-9120(21)00303-9. [PMID: 34788635 DOI: 10.1016/j.clinbiochem.2021.11.004] [Reference Citation Analysis]
107 Manders E, Rain S, Bogaard HJ, Handoko ML, Stienen GJ, Vonk-Noordegraaf A, Ottenheijm CA, de Man FS. The striated muscles in pulmonary arterial hypertension: adaptations beyond the right ventricle. Eur Respir J 2015;46:832-42. [PMID: 26113677 DOI: 10.1183/13993003.02052-2014] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
108 Morris TA. Why acute pulmonary embolism becomes chronic thromboembolic pulmonary hypertension: clinical and genetic insights. Curr Opin Pulm Med 2013;19:422-9. [PMID: 23907454 DOI: 10.1097/MCP.0b013e328364379f] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
109 Liu J, Yang P, Tian H, Zhen K, Mccabe C, Zhao L, Zhai Z. Right ventricle remodeling in chronic thromboembolic pulmonary hypertension. Journal of Translational Internal Medicine 2022;0. [DOI: 10.2478/jtim-2022-0027] [Reference Citation Analysis]
110 Agarwal R, Gomberg-maitland M. Prognostication in Pulmonary Arterial Hypertension. Heart Failure Clinics 2012;8:373-83. [DOI: 10.1016/j.hfc.2012.04.011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
111 Potus F, Mai V, Lebret M, Malenfant S, Breton-Gagnon E, Lajoie AC, Boucherat O, Bonnet S, Provencher S. Novel insights on the pulmonary vascular consequences of COVID-19. Am J Physiol Lung Cell Mol Physiol 2020;319:L277-88. [PMID: 32551862 DOI: 10.1152/ajplung.00195.2020] [Cited by in Crossref: 51] [Cited by in F6Publishing: 43] [Article Influence: 25.5] [Reference Citation Analysis]
112 D'armini AM. Diagnostic advances and opportunities in chronic thromboembolic pulmonary hypertension. Eur Respir Rev 2015;24:253-62. [DOI: 10.1183/16000617.00000915] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
113 Li ZF, Zhou DX, Wang QB, Pan WZ, Zhang L, Ge JB. Plasma N-terminal pro-brain natriuretic peptide levels are positively correlated with pulmonary arterial pressure in atrial septal defect patients. Regul Pept 2013;183:13-6. [PMID: 23499807 DOI: 10.1016/j.regpep.2013.03.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
114 Yanartas M, Kalkan ME, Arslan A, Tas SG, Koksal C, Bekiroglu N, Yildizeli B. Neutrophil/Lymphocyte Ratio Can Predict Postoperative Mortality in Patients with Chronic Thromboembolic Pulmonary Hypertension. Ann Thorac Cardiovasc Surg 2015;21:229-35. [PMID: 25753325 DOI: 10.5761/atcs.oa.14-00190] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
115 Boulate D, Perros F, Dorfmuller P, Arthur-ataam J, Guihaire J, Lamrani L, Decante B, Humbert M, Eddahibi S, Dartevelle P, Fadel E, Mercier O. Pulmonary microvascular lesions regress in reperfused chronic thromboembolic pulmonary hypertension. The Journal of Heart and Lung Transplantation 2015;34:457-67. [DOI: 10.1016/j.healun.2014.07.005] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
116 Granton J, Langleben D, Kutryk MB, Camack N, Galipeau J, Courtman DW, Stewart DJ. Endothelial NO-Synthase Gene-Enhanced Progenitor Cell Therapy for Pulmonary Arterial Hypertension: The PHACeT Trial. Circ Res. 2015;117:645-654. [PMID: 26195220 DOI: 10.1161/circresaha.114.305951] [Cited by in Crossref: 81] [Cited by in F6Publishing: 47] [Article Influence: 11.6] [Reference Citation Analysis]
117 Harhay MO, Tracy RP, Bagiella E, Barr RG, Pinder D, Hundley WG, Bluemke DA, Kronmal RA, Lima JA, Kawut SM. Relationship of CRP, IL-6, and fibrinogen with right ventricular structure and function: the MESA-Right Ventricle Study. Int J Cardiol 2013;168:3818-24. [PMID: 23932860 DOI: 10.1016/j.ijcard.2013.06.028] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 4.1] [Reference Citation Analysis]
118 Ross AF, Ueda K. Pulmonary hypertension in thoracic surgical patients. Current Opinion in Anaesthesiology 2010;23:25-33. [DOI: 10.1097/aco.0b013e328334cb59] [Cited by in Crossref: 17] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
119 Stickel S, Gin-Sing W, Wagenaar M, Gibbs JSR. The practical management of fluid retention in adults with right heart failure due to pulmonary arterial hypertension. Eur Heart J Suppl 2019;21:K46-53. [PMID: 31857800 DOI: 10.1093/eurheartj/suz207] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
120 Dewachter L, Dewachter C, Naeije R. New therapies for pulmonary arterial hypertension: an update on current bench to bedside translation. Expert Opin Investig Drugs 2010;19:469-88. [PMID: 20367190 DOI: 10.1517/13543781003727099] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
121 Cucci AR, Kline JA, Lahm T. Acute Right Ventricular Failure. In: Voelkel NF, Schranz D, editors. The Right Ventricle in Health and Disease. New York: Springer; 2015. pp. 161-205. [DOI: 10.1007/978-1-4939-1065-6_9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
122 Yang M, Deng C, Wu D, Zhong Z, Lv X, Huang Z, Lian N, Liu K, Zhang Q. The role of mononuclear cell tissue factor and inflammatory cytokines in patients with chronic thromboembolic pulmonary hypertension. J Thromb Thrombolysis 2016;42:38-45. [PMID: 26667361 DOI: 10.1007/s11239-015-1323-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
123 Rhodes CJ, Wharton J, Wilkins MR. Pulmonary Hypertension: Biomarkers. In: Humbert M, Evgenov OV, Stasch J, editors. Pharmacotherapy of Pulmonary Hypertension. Berlin: Springer Berlin Heidelberg; 2013. pp. 77-103. [DOI: 10.1007/978-3-662-45805-1_4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
124 Aldabbous L, Abdul-Salam V, McKinnon T, Duluc L, Pepke-Zaba J, Southwood M, Ainscough AJ, Hadinnapola C, Wilkins MR, Toshner M, Wojciak-Stothard B. Neutrophil Extracellular Traps Promote Angiogenesis: Evidence From Vascular Pathology in Pulmonary Hypertension. Arterioscler Thromb Vasc Biol 2016;36:2078-87. [PMID: 27470511 DOI: 10.1161/ATVBAHA.116.307634] [Cited by in Crossref: 66] [Cited by in F6Publishing: 45] [Article Influence: 11.0] [Reference Citation Analysis]
125 Kimura Y, Weiss JE, Haroldson KL, Lee T, Punaro M, Oliveira S, Rabinovich E, Riebschleger M, Antón J, Blier PR, Gerloni V, Hazen MM, Kessler E, Onel K, Passo MH, Rennebohm RM, Wallace CA, Woo P, Wulffraat N; Childhood Arthritis Rheumatology Research Alliance Carra Net Investigators. Pulmonary hypertension and other potentially fatal pulmonary complications in systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) 2013;65:745-52. [PMID: 23139240 DOI: 10.1002/acr.21889] [Cited by in Crossref: 77] [Cited by in F6Publishing: 62] [Article Influence: 8.6] [Reference Citation Analysis]
126 Mahmud E, Madani MM, Kim NH, Poch D, Ang L, Behnamfar O, Patel MP, Auger WR. Chronic Thromboembolic Pulmonary Hypertension: Evolving Therapeutic Approaches for Operable and Inoperable Disease. J Am Coll Cardiol 2018;71:2468-86. [PMID: 29793636 DOI: 10.1016/j.jacc.2018.04.009] [Cited by in Crossref: 57] [Cited by in F6Publishing: 42] [Article Influence: 19.0] [Reference Citation Analysis]
127 Scognamiglio G, Kempny A, Price LC, Alonso-gonzalez R, Marino P, Swan L, D’ Alto M, Hooper J, Gatzoulis MA, Dimopoulos K, Wort SJ. C-reactive protein in adults with pulmonary arterial hypertension associated with congenital heart disease and its prognostic value. Heart 2014;100:1335-41. [DOI: 10.1136/heartjnl-2014-305494] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
128 Yoshihisa A, Kimishima Y, Kiko T, Sato Y, Watanabe S, Kanno Y, Abe S, Miyata-tatsumi M, Sato T, Suzuki S, Oikawa M, Kobayashi A, Yamaki T, Sugimoto K, Kunii H, Nakazato K, Suzuki H, Ishida T, Takeishi Y. Liver fibrosis marker, 7S domain of collagen type IV, in patients with pre-capillary pulmonary hypertension. International Journal of Cardiology 2018;258:269-74. [DOI: 10.1016/j.ijcard.2018.01.138] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
129 Delcroix M, Torbicki A, Gopalan D, Sitbon O, Klok FA, Lang I, Jenkins D, Kim NH, Humbert M, Jais X, Vonk Noordegraaf A, Pepke-Zaba J, Brénot P, Dorfmuller P, Fadel E, Ghofrani HA, Hoeper MM, Jansa P, Madani M, Matsubara H, Ogo T, Grünig E, D'Armini A, Galie N, Meyer B, Corkery P, Meszaros G, Mayer E, Simonneau G. ERS statement on chronic thromboembolic pulmonary hypertension. Eur Respir J 2021;57:2002828. [PMID: 33334946 DOI: 10.1183/13993003.02828-2020] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 13.0] [Reference Citation Analysis]
130 Pritts CD, Pearl RG. Anesthesia for patients with pulmonary hypertension: . Current Opinion in Anaesthesiology 2010;23:411-6. [DOI: 10.1097/aco.0b013e32833953fb] [Cited by in Crossref: 66] [Cited by in F6Publishing: 14] [Article Influence: 5.5] [Reference Citation Analysis]
131 Okina N, Ohuchida M, Takeuchi T, Fujiyama T, Satoh A, Sakamoto T, Adachi H, Imaizumi T. Utility of measuring C-reactive protein for prediction of in-hospital events in patients with acute aortic dissection. Heart Vessels 2013;28:330-5. [PMID: 22570140 DOI: 10.1007/s00380-012-0257-2] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
132 Tielemans B, Delcroix M, Belge C, Quarck R. TGFβ and BMPRII signalling pathways in the pathogenesis of pulmonary arterial hypertension. Drug Discovery Today 2019;24:703-16. [DOI: 10.1016/j.drudis.2018.12.001] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 8.3] [Reference Citation Analysis]
133 Geenen LW, Baggen VJM, Koudstaal T, Boomars KA, Eindhoven JA, Boersma E, Roos-Hesselink JW, van den Bosch AE. The prognostic value of various biomarkers in adults with pulmonary hypertension; a multi-biomarker approach. Am Heart J 2019;208:91-9. [PMID: 30580131 DOI: 10.1016/j.ahj.2018.11.001] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
134 Foris V, Kovacs G, Tscherner M, Olschewski A, Olschewski H. Biomarkers in pulmonary hypertension: what do we know? Chest 2013;144:274-83. [PMID: 23880678 DOI: 10.1378/chest.12-1246] [Cited by in Crossref: 58] [Cited by in F6Publishing: 57] [Article Influence: 6.4] [Reference Citation Analysis]
135 Kikuchi N, Satoh K, Satoh T, Yaoita N, Siddique MAH, Omura J, Kurosawa R, Nogi M, Sunamura S, Miyata S, Misu H, Saito Y, Shimokawa H. Diagnostic and Prognostic Significance of Serum Levels of SeP (Selenoprotein P) in Patients With Pulmonary Hypertension. Arterioscler Thromb Vasc Biol 2019;39:2553-62. [PMID: 31665907 DOI: 10.1161/ATVBAHA.119.313267] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
136 Heresi GA, Aytekin M, Newman J, DiDonato J, Dweik RA. Plasma levels of high-density lipoprotein cholesterol and outcomes in pulmonary arterial hypertension. Am J Respir Crit Care Med 2010;182:661-8. [PMID: 20448092 DOI: 10.1164/rccm.201001-0007OC] [Cited by in Crossref: 78] [Cited by in F6Publishing: 45] [Article Influence: 6.5] [Reference Citation Analysis]
137 Yan L, Li X, Liu Z, Zhao Z, Luo Q, Zhao Q, Jin Q, Yu X, Zhang Y. Research progress on the pathogenesis of CTEPH. Heart Fail Rev. 2019;24:1031-1040. [PMID: 31087212 DOI: 10.1007/s10741-019-09802-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
138 Galiè N, Humbert M, Vachiery J, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beghetti M, Ghofrani A, Gomez Sanchez MA, Hansmann G, Klepetko W, Lancellotti P, Matucci M, Mcdonagh T, Pierard LA, Trindade PT, Zompatori M, Hoeper M. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS)Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J 2015;46:903-75. [DOI: 10.1183/13993003.01032-2015] [Cited by in Crossref: 1413] [Cited by in F6Publishing: 1183] [Article Influence: 201.9] [Reference Citation Analysis]
139 Mercurio V, Cuomo A, Naranjo M, Hassoun PM. Inflammatory Mechanisms in the Pathogenesis of Pulmonary Arterial Hypertension: Recent Advances. Compr Physiol 2021;11:1805-29. [PMID: 33792903 DOI: 10.1002/cphy.c200025] [Reference Citation Analysis]
140 Perrotta F, Nigro E, Mollica M, Costigliola A, D'Agnano V, Daniele A, Bianco A, Guerra G. Pulmonary Hypertension and Obesity: Focus on Adiponectin. Int J Mol Sci 2019;20:E912. [PMID: 30791536 DOI: 10.3390/ijms20040912] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 8.7] [Reference Citation Analysis]
141 Leary PJ, Jenny NS, Barr RG, Bluemke DA, Harhay MO, Heckbert SR, Kronmal RA, Lima JA, Mikacenic C, Tracy RP, Kawut SM. Pentraxin-3 and the right ventricle: the Multi-Ethnic Study of Atherosclerosis-Right Ventricle Study. Pulm Circ 2014;4:250-9. [PMID: 25006444 DOI: 10.1086/675988] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
142 Simonneau G, Torbicki A, Dorfmüller P, Kim N. The pathophysiology of chronic thromboembolic pulmonary hypertension. Eur Respir Rev 2017;26:160112. [DOI: 10.1183/16000617.0112-2016] [Cited by in Crossref: 134] [Cited by in F6Publishing: 108] [Article Influence: 26.8] [Reference Citation Analysis]
143 Zabini D, Heinemann A, Foris V, Nagaraj C, Nierlich P, Bálint Z, Kwapiszewska G, Lang IM, Klepetko W, Olschewski H, Olschewski A. Comprehensive analysis of inflammatory markers in chronic thromboembolic pulmonary hypertension patients. Eur Respir J 2014;44:951-62. [PMID: 25034560 DOI: 10.1183/09031936.00145013] [Cited by in Crossref: 62] [Cited by in F6Publishing: 51] [Article Influence: 7.8] [Reference Citation Analysis]
144 Liu J, Lin L, Yao P, Zhao W, Hu J, Shi XH, Zhang S, Zhu X, Pang DW, Liu AA. Immunoprofiling of Severity and Stage of Bacterial Infectious Diseases by Ultrabright Fluorescent Nanosphere-Based Dyad Test Strips. Anal Chem 2022;94:8818-26. [PMID: 35686482 DOI: 10.1021/acs.analchem.2c02028] [Reference Citation Analysis]
145 Galiè N, Humbert M, Vachiery J, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beghetti M, Ghofrani A, Gomez Sanchez MA, Hansmann G, Klepetko W, Lancellotti P, Matucci M, Mcdonagh T, Pierard LA, Trindade PT, Zompatori M, Hoeper M. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS)Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 2015;37:67-119. [DOI: 10.1093/eurheartj/ehv317] [Cited by in Crossref: 2814] [Cited by in F6Publishing: 2398] [Article Influence: 402.0] [Reference Citation Analysis]
146 Hoendermis ES. Pulmonary arterial hypertension: an update. Neth Heart J 2011;19:514-22. [PMID: 22083429 DOI: 10.1007/s12471-011-0222-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
147 Ahmadi A, Ohira H, Mielniczuk LM. FDG PET Imaging for Identifying Pulmonary Hypertension and Right Heart Failure. Curr Cardiol Rep 2015;17. [DOI: 10.1007/s11886-014-0555-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
148 Wynants M, Vengethasamy L, Ronisz A, Meyns B, Delcroix M, Quarck R. NF-κB pathway is involved in CRP-induced effects on pulmonary arterial endothelial cells in chronic thromboembolic pulmonary hypertension. American Journal of Physiology-Lung Cellular and Molecular Physiology 2013;305:L934-42. [DOI: 10.1152/ajplung.00034.2013] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]